131I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study

Ko, Kuan‐Yin; Kao, Chia‐Hung; Lin, Cheng‐Li; Huang, Wen-Sheng; Yen, Ruoh‐Fang

doi:10.1007/s00259-015-3055-0

Cited by 39 publications

(29 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Controversy concerning the effect of 131 I treatment on the occurrence of SPM in patients with thyroid cancer persists [ 8 , 19 , 20 ]. Previous studies had different study designs, varying follow-up periods, and different 131 I dosages, which made an accurate comparison difficult.…”

Section: Discussionmentioning

confidence: 99%

“…To avoid the over- or underadministration of postthyroidectomy therapeutic modalities in patients with thyroid cancer, the stratification of the risk of recurrence and thyroid cancer mortality is urgently needed [ 5 , 6 ]. An elevated risk of second primary malignancy (SPM), possibly related to radioactive iodide ( 131 I), was recently reported in patients with thyroid cancer [ 7 , 8 ]. During the follow-up period, the diagnosis and identification of SPM risk factors in patients with well-differentiated thyroid cancer are important.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Outcome of Second Primary Malignancies in Patients with Well-Differentiated Thyroid Cancer

Liou

Tsang

Chao

et al. 2016

International Journal of Endocrinology

View full text Add to dashboard Cite

Background. The aims of this study were to analyze the clinical characteristics of SPM in patients with well-differentiated thyroid cancer and to determine the long-term prognosis in patients with double malignancies. Materials and Methods. We retrospectively analyzed 2,864 patients with well-differentiated thyroid cancer and a mean age of 44.0 ± 14.4 years. Of these, 200 (7.0%) were diagnosed with SPM, 115 of which were diagnosed with metachronous SPM. Results. Of 2,864 patients, 163 (5.7%) patients died of thyroid cancer and 301 (10.5%) died of any cause by the end of the follow-up period. Multivariate analysis identified age, SPM, external radiotherapy, TNM stage, and postoperative serum Tg level to be factors independently associated with decreased survival. Of 200 patients with SPM, 74 (37.0%) died. In comparison to the anachronous and synchronous groups, the metachronous SPM group had a higher mean age; more advanced tumor, node, and metastasis stage; lower remission rate; higher postoperative radioactive iodide (131I) accumulated dose; a higher proportion of patients who underwent external radiotherapy; and higher thyroid cancer and total mortality rates. Conclusions. Patients with well-differentiated thyroid carcinoma and metachronous SPM had worse prognoses compared to patients without SPM.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Therapeutic Outcome of Second Primary Malignancies in Patients with Well-Differentiated Thyroid Cancer

Liou

Tsang

Chao

et al. 2016

International Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…There is a small, but consistently higher, incidence of secondary primary malignancy in patients treated with 131 I (Lang, Wong, Wong, Cowling, & Wan, 2012;Ko, Kao, Lin, Huang, & Yen, 2015),…”

Section: Treatment Of Salivary Gland Dysfunctionmentioning

confidence: 98%

“…There is a small, but consistently higher, incidence of secondary primary malignancy in patients treated with 131 I (Lang, Wong, Wong, Cowling, & Wan, ; Ko, Kao, Lin, Huang, & Yen, ), and the use of viral vectors that carry a risk of insertional mutagenesis should be weighed. In this regard, episomal viral vectors, non‐viral gene transfer, or alternately, direct protein transfer, are safer options.…”

Section: Treatment Of Salivary Gland Dysfunctionmentioning

confidence: 99%

Radioactive iodine: An unappreciated threat to salivary gland function

Sunavala‐Dossabhoy

2018

Oral Diseases

View full text Add to dashboard Cite

Thyroid cancer is an endocrine malignancy whose prevalence is increasing in the United States. Nearly 57,000 new cases of thyroid cancer are estimated to be diagnosed in 2017. The standard of care for differentiated thyroid cancer is thyroidectomy followed by ablation of thyroid remnants with high-dose radioactive iodine ( I). Apart from thyroid glands, I accumulates in cells of salivary glands and compromises its function. Xerostomia is, therefore, a frequent and often persistent complaint of patients. Despite adoption of standard preventive measures, parenchymal damage and chronic salivary dysfunction are observed in a substantial number of patients. Saliva is important for oral homeostasis, and its reduction increases the risk of oral morbidity. As differentiated thyroid cancer patients have an excellent survival rate, preservation of salivary gland function carries added significance. A focus on treatments that preserve or restore long-term salivary flow can significantly improve the quality of life of thyroid cancer survivors.

show abstract

“…The dose-response relationships were linear, which illustrated that a treatment of 3.7 GBq of 131 I could theoretically induce an excess of 53 solid malignant tumors and 3 leukemias, in 10,000 patients during 10 y of follow-up. However, another study reported that there was no statistical difference in risk of second primary cancer between highand low-doses of 131 I for the treatment of differentiated thyroid cancer (Ko et al 2015). As of now, the general consensus on the risk associated with 131 I therapy seems that the evidence of serious risks associated with the therapy is weak and contradictory, and then, the potential risk of adverse effects must be weighed against the risk of dying from recurrent thyroid cancer (which is >8% in a 30-year followup period of patients not treated with 131 I therapy) (Blumhardt et al 2014).…”

Section: Second Primary Cancer In Radionuclide Therapymentioning

confidence: 99%

Radiation protection in therapy with radiopharmaceuticals

Hosono

2018

International Journal of Radiation Biology

View full text Add to dashboard Cite

Purpose: Radionuclide therapy (RNT) involves the selective delivery of radiation, emitted from radionuclides to tumors or target organs. The techniques of RNT are increasingly being used for the treatment of various tumors. The purpose of this article is to report on the current state of RNT, to clarify the issues of radiation protection associated with RNT, and to show future prospects. Results and conclusions: Medical exposure of patients has unique features; application of dose limits is not undertaken, and justification and optimization do apply but in a different way from in other exposures. The expanding use of RNT has raised concern regarding potential carcinogenic and leukemogenic effects and research on second primary cancer after RNT have been developing. RNT combined with imaging and dosimetry and featuring a theranostic approach is undergoing a significant expansion, and such dosimetry-based treatment planning leads to individualization, or personalization, which is likely to improve the effectiveness and safety of patient management in RNT.

show abstract

131I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study

Cited by 39 publications

References 27 publications

Therapeutic Outcome of Second Primary Malignancies in Patients with Well-Differentiated Thyroid Cancer

Therapeutic Outcome of Second Primary Malignancies in Patients with Well-Differentiated Thyroid Cancer

Radioactive iodine: An unappreciated threat to salivary gland function

Radiation protection in therapy with radiopharmaceuticals

Contact Info

Product

Resources

About